留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

应中央军委要求,2022年9月起,《药学实践杂志》将更名为《药学实践与服务》,双月刊,正文96页;2023年1月起,拟出版月刊,正文64页,数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿!

1例帕金森病伴部分精神障碍患者的用药分析和药学监护

徐栋丽 应茵 陆绪亮 宋洪涛 戴海斌

徐栋丽, 应茵, 陆绪亮, 宋洪涛, 戴海斌. 1例帕金森病伴部分精神障碍患者的用药分析和药学监护[J]. 药学实践与服务, 2017, 35(5): 460-462,465. doi: 10.3969/j.issn.1006-0111.2017.05.019
引用本文: 徐栋丽, 应茵, 陆绪亮, 宋洪涛, 戴海斌. 1例帕金森病伴部分精神障碍患者的用药分析和药学监护[J]. 药学实践与服务, 2017, 35(5): 460-462,465. doi: 10.3969/j.issn.1006-0111.2017.05.019
XU Dongli, YING Yin, LU Xuliang, SONG Hongtao, DAI Haibin. Medication analysis and pharmaceutical care for a Parkinson's disease patient with mental disorders[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(5): 460-462,465. doi: 10.3969/j.issn.1006-0111.2017.05.019
Citation: XU Dongli, YING Yin, LU Xuliang, SONG Hongtao, DAI Haibin. Medication analysis and pharmaceutical care for a Parkinson's disease patient with mental disorders[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(5): 460-462,465. doi: 10.3969/j.issn.1006-0111.2017.05.019

1例帕金森病伴部分精神障碍患者的用药分析和药学监护

doi: 10.3969/j.issn.1006-0111.2017.05.019

Medication analysis and pharmaceutical care for a Parkinson's disease patient with mental disorders

  • 摘要: 目的 探讨临床药师在帕金森病伴部分精神障碍患者治疗过程中的作用。 方法 临床药师结合患者疾病特点、用药史、药物相互作用及药品不良反应等情况,对患者进行药学监护并提出优化治疗方案的建议。 结果 临床药师参与患者治疗方案的制订,进行用药指导和出院教育,促进合理用药。 结论 临床药师可利用自身专业知识,积极参与临床药物治疗工作,协同医师优化临床给药方案。
  • [1] 中华医学会神经病学分会帕金森病及运动障碍学组. 中国帕金森病治疗指南(第三版)[J]. 中华神经科杂志, 2014, 47(6):428-433.
    [2] 王惠霞,武新安,何忠芳. 帕金森病一例药学监护实践[J]. 临床合理用药杂志, 2012,12(5): 85-86.
    [3] Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines[S]. Neurology, 2001,56(11): S1-S88.
    [4] 刘春风,尹伟华,罗蔚锋.帕金森病患者运动障碍和症状波动的影响因素[J].中华神经科杂志,2003, 36(6): 411-413.
    [5] Zhang ZX, Chen H, Chen SD, et al.Chinese culture permeation in the treatment of Parkinson disease:a cross-sectional study in four regions of China[J]. BMC Res Notes, 2014, 7: 65.
    [6] Warren Olanow C, Kieburtz K, Rascol O, et al. Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease[J]. Mov Disord, 2013, 28(8):1064-1071.
    [7] 中华医学会神经病学分会神经心理学与行为神经病学组, 中华医学会神经病学分会神经心理学与行为神经病学组. 帕金森病抑郁、焦虑及精神病性障碍的诊断标准及治疗指南[J].中华神经科杂志,2013,46(1):56-60.
    [8] 江开达.中华医学会精神科分会.抑郁障碍防治指南[M].北京:北京大学医学出版社,2007:21.
    [9] Barone P,Poewe W,Albrecht S,et al.Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease:a randomised,double-blind,Placebo-controlled trial[J].Lancet Neurol,2010,9(6):573-580.
    [10] O'Sullivan SS, Williams DR, Gallagher DA, et al. Nonmotor symptoms as presenting complaints in Parkinson's disease: a clinicopathological study[J]. Mov Disord, 2008, 23(1): 101-106.
    [11] Duncan GW, Khoo TK, Yarnall AJ, et al. Health-related quality of life in early Parkinson's disease: the impact of nonmotor symptoms[J]. Mov Disord, 2014, 29(2):195-202.
    [12] Shiba M, Bower JH, Maraganore DM, et al. Anxiety disorders and depressive disorders preceding Parkinson's disease: a case-control study[J]. Mov Disord, 2000,15(4): 669-677.
    [13] Leentjens AF, Van den Akker M, Metsemakers JF, et al. Higher incidence of depression preceding the onset of Parkinson's disease: a register study[J]. Mov Disord, 2003,18(4): 414-418.
    [14] Gonera EG, van't Hof M, Berger HJ, et al. Symptoms and duration of the prodromal phase in Parkinson's disease[J]. Mov Disord, 1997,12(6): 871-876.
    [15] Shen CC,Tsai SJ, Perng CL, et al. Risk of Parkinson disease after depression: a nationwide population-based study[J]. Neurology,2013, 81(17): 1538-1544.
    [16] Breier A, Sutton V, Feldman PD, et al. Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease[J]. Biol Psychiatry,2002, 52(5): 438-445.
    [17] Ondo WG, Levy JK, Vuong KD, et al. Olanzapine treatnlent for dopaminergic-induced hallucinations[J]. Mov Disord, 2002, 17(5):1031-1035.
    [18] Goetz CG, Blasucci LM, Leurgans S, et al. Olanzapine and clozapine:comparative effects on motor function in hallucinating PD patients[J]. Neurology,2000, 55(6): 789-794.
    [19] Friedman JH. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease[J]. Neuorlogy,1998, 50(4):1195-1196.
    [20] Seppi K, Weintraub D, Coelho M, et a1. The movement disorder society evidence-based medicine review update:treatments for the non-motor symptoms of Parkinson's disease[J]. Mov Disord,2011, 26(3): S42-80.
  • [1] 王耀振, 徐灿, 吕顺莉, 田泾, 张东炜.  钾离子竞争性酸阻滞剂的药学特征研究进展 . 药学实践与服务, 2024, 42(7): 278-284. doi: 10.12206/j.issn.2097-2024.202306040
    [2] 徐飞, 陈瑾, 鲁育含, 李志勇.  肠道菌群参与糖尿病肾病的机制研究进展 . 药学实践与服务, 2024, 42(5): 181-184, 197. doi: 10.12206/j.issn.2097-2024.202312023
  • 加载中
计量
  • 文章访问数:  2619
  • HTML全文浏览量:  275
  • PDF下载量:  935
  • 被引次数: 0
出版历程
  • 收稿日期:  2016-03-03
  • 修回日期:  2016-09-06

1例帕金森病伴部分精神障碍患者的用药分析和药学监护

doi: 10.3969/j.issn.1006-0111.2017.05.019

摘要: 目的 探讨临床药师在帕金森病伴部分精神障碍患者治疗过程中的作用。 方法 临床药师结合患者疾病特点、用药史、药物相互作用及药品不良反应等情况,对患者进行药学监护并提出优化治疗方案的建议。 结果 临床药师参与患者治疗方案的制订,进行用药指导和出院教育,促进合理用药。 结论 临床药师可利用自身专业知识,积极参与临床药物治疗工作,协同医师优化临床给药方案。

English Abstract

徐栋丽, 应茵, 陆绪亮, 宋洪涛, 戴海斌. 1例帕金森病伴部分精神障碍患者的用药分析和药学监护[J]. 药学实践与服务, 2017, 35(5): 460-462,465. doi: 10.3969/j.issn.1006-0111.2017.05.019
引用本文: 徐栋丽, 应茵, 陆绪亮, 宋洪涛, 戴海斌. 1例帕金森病伴部分精神障碍患者的用药分析和药学监护[J]. 药学实践与服务, 2017, 35(5): 460-462,465. doi: 10.3969/j.issn.1006-0111.2017.05.019
XU Dongli, YING Yin, LU Xuliang, SONG Hongtao, DAI Haibin. Medication analysis and pharmaceutical care for a Parkinson's disease patient with mental disorders[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(5): 460-462,465. doi: 10.3969/j.issn.1006-0111.2017.05.019
Citation: XU Dongli, YING Yin, LU Xuliang, SONG Hongtao, DAI Haibin. Medication analysis and pharmaceutical care for a Parkinson's disease patient with mental disorders[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(5): 460-462,465. doi: 10.3969/j.issn.1006-0111.2017.05.019
参考文献 (20)

目录

    /

    返回文章
    返回